November 25, 2022
Closing trading at 1 p.m.; month’s end – Wednesday of next week
Indications: 1 Sell into Strength, 1 positive Indication and 1 Negative Indication
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
I don’t seek fame, do podcasts or give speeches; what I do is write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!
8:00 a.m. edition
November 24, 2022
Give thanks for .... unknown blessings already on their way!
There's more...
November 25, 2022
you understand the CEO's vision and how many different “fallbacks” it has; so, if one goes wrong, it's not the end of the world?
Pre-open Indications: 1 Hit and 2 Miss
It’s an honor to be considered the “canary in the (sector) coal mine”! It’s more than opinion, the facts and truth need to be recognized!
Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write
Your portfolio should be profiting from RMi’s analysis -SUBSCRIBE!
Week’s end and in review
November 24, 2022
Give thanks for .... unknown blessings already on their way! There's more...
November 15, 2022
The stock is trading at $0.39.09 (+0.72% or +$0.0028) as compared to tender offer of $0.34 A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement of specified milestones. Investors NEED to tender; a NON vote will render the company bankrupt, liquidated and investors will get NOTHING!
November 10, 2022
BCLI is down -$1.39 or -48.09% and fluctuating BCLI has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Biologics License Application (BLA) for NurOwn for the treatment of ALS. The FDA has indicated that the company can request a Type A meeting to discuss the content of the refusal to file letter.
November 25, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector equities faltered Friday in a subdued trading session.
November 25, 2022
RegMed Investors’ (RMi) pre-open: shortened trading session ends week
November 24, 2022
Happy Thanksgiving ... giving thanks and be SAFE!
November 23, 2022
RegMed Investors’ (RMi) closing bell: gobble, gobble; share pricing heated-up
November 23, 2022
RegMed Investors’ (RMi) pre-open: time to travel defensively while awaiting Fed minutes
November 22, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy companies are swing to the upside after four (4) declining sessions
November 22, 2022
RegMed Investors’ (RMi) pre-open: be mindful of frazzled sector
November 21, 2022
RegMed Investors’ (RMi) closing bell: short, holiday interrupted week
November 21, 2022
RegMed Investors’ (RMi) pre-open: key word: resistance
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
